A61P25/24

Probiotic formulation for reducing stress, anxiety and depression
20230009438 · 2023-01-12 ·

Stress is any demand placed on the brain or physical body, thereby leading to anxiety and depression and it is a common phenomenon experienced by humans and animals. Stress, anxiety and depression often leads to serious mental ill health. People with anxiety disorders respond to certain things or situations with fear and dread and display physical signs such as a pounding heart and sweating. Often, people lose their willpower, concentration and interest in day to day activities, are drained of energy and can even become devoid of any emotion.

It is documented that low activity of certain neurotransmitters can result in anxiety, chronic stress, depression, difficulty in concentrating, memory problems, muscle pain, headaches, insomnia and sleep problems. Therefore, if the level of these neurotransmitters is raised, the problem of stress, anxiety and depression can be cured. The invention describes a formulation to naturally increase the levels of certain neurotransmitters in the body, thereby reducing stress, anxiety and depression.

Probiotic formulation for reducing stress, anxiety and depression
20230009438 · 2023-01-12 ·

Stress is any demand placed on the brain or physical body, thereby leading to anxiety and depression and it is a common phenomenon experienced by humans and animals. Stress, anxiety and depression often leads to serious mental ill health. People with anxiety disorders respond to certain things or situations with fear and dread and display physical signs such as a pounding heart and sweating. Often, people lose their willpower, concentration and interest in day to day activities, are drained of energy and can even become devoid of any emotion.

It is documented that low activity of certain neurotransmitters can result in anxiety, chronic stress, depression, difficulty in concentrating, memory problems, muscle pain, headaches, insomnia and sleep problems. Therefore, if the level of these neurotransmitters is raised, the problem of stress, anxiety and depression can be cured. The invention describes a formulation to naturally increase the levels of certain neurotransmitters in the body, thereby reducing stress, anxiety and depression.

COMPOSITIONS AND METHODS FOR TREATING DEPRESSION
20230210930 · 2023-07-06 · ·

Disclosed are a novel combination of specific therapeutics selected from S-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression.

USES OF A CAROTENOID IN THE TREATMENT OR PREVENTION OF STRESS INDUCED CONDITIONS

The invention relates to a carotenoid for use in the treatment or prevention of stress induced conditions, and in particular it relates to the treatment or prevention of a disease mediated by glucocorticoid receptor activity. The invention also relates to a cosmetic method for preventing premature-aging of skin in a subject which comprises administering a carotenoid to said subject. Finally, the invention relates to a method for modulating the activity of a glucocorticoid receptor comprising contacting the receptor with a carotenoid.

USES OF A CAROTENOID IN THE TREATMENT OR PREVENTION OF STRESS INDUCED CONDITIONS

The invention relates to a carotenoid for use in the treatment or prevention of stress induced conditions, and in particular it relates to the treatment or prevention of a disease mediated by glucocorticoid receptor activity. The invention also relates to a cosmetic method for preventing premature-aging of skin in a subject which comprises administering a carotenoid to said subject. Finally, the invention relates to a method for modulating the activity of a glucocorticoid receptor comprising contacting the receptor with a carotenoid.

PROCESS FOR PREPARING SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINES

A process for preparing a compound of Formula (1a):

##STR00001##

or a pharmaceutically acceptable salt thereof.

TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
20230210872 · 2023-07-06 ·

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
20230210872 · 2023-07-06 ·

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

TRANSDERMAL DRUG DELIVERY DEVICES HAVING PSILOCYBIN, LYSERGIC ACID DIETHYLAMIDE OR 3,4-METHYLENEDIOXYMETHAMPHETAMINE COATED MICROPROTRUSIONS
20230210762 · 2023-07-06 · ·

Disclosed herein are compositions, devices and methods employing therapeutic concentrations of psilocybin, LSD or MDMA for the treatment of certain health conditions, including depression, anxiety, post-traumatic stress disorder, migraine and cluster headache. Also described are methods and apparatuses to deliver psilocybin, LSD or MDMA by intracutaneous administration via microneedle administration.

TRANSDERMAL DRUG DELIVERY DEVICES HAVING PSILOCYBIN, LYSERGIC ACID DIETHYLAMIDE OR 3,4-METHYLENEDIOXYMETHAMPHETAMINE COATED MICROPROTRUSIONS
20230210762 · 2023-07-06 · ·

Disclosed herein are compositions, devices and methods employing therapeutic concentrations of psilocybin, LSD or MDMA for the treatment of certain health conditions, including depression, anxiety, post-traumatic stress disorder, migraine and cluster headache. Also described are methods and apparatuses to deliver psilocybin, LSD or MDMA by intracutaneous administration via microneedle administration.